208 related articles for article (PubMed ID: 33077751)
1. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma.
Wellens LM; Deken MM; Sier CFM; Johnson HR; de la Jara Ortiz F; Bhairosingh SS; Houvast RD; Kholosy WM; Baart VM; Pieters AMMJ; de Krijger RR; Molenaar JJ; Wehrens EJ; Dekkers JF; Wijnen MHWA; Vahrmeijer AL; Rios AC
Sci Rep; 2020 Oct; 10(1):17667. PubMed ID: 33077751
[TBL] [Abstract][Full Text] [Related]
2. Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma.
Privitera L; Waterhouse DJ; Preziosi A; Paraboschi I; Ogunlade O; Da Pieve C; Barisa M; Ogunbiyi O; Weitsman G; Hutchinson JC; Cross K; Biassoni L; Stoyanov D; Sebire N; Beard P; De Coppi P; Kramer-Marek G; Anderson J; Giuliani S
Cancer Res; 2023 Jun; 83(12):2077-2089. PubMed ID: 36934744
[TBL] [Abstract][Full Text] [Related]
3. Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.
Tang C; Du Y; Liang Q; Cheng Z; Tian J
Mol Imaging Biol; 2020 Jun; 22(3):476-485. PubMed ID: 31228075
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW.
Warram JM; de Boer E; Korb M; Hartman Y; Kovar J; Markert JM; Gillespie GY; Rosenthal EL
Br J Neurosurg; 2015; 29(6):850-8. PubMed ID: 26073144
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
6. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using
Li D; Zhang J; Chi C; Xiao X; Wang J; Lang L; Ali I; Niu G; Zhang L; Tian J; Ji N; Zhu Z; Chen X
Theranostics; 2018; 8(9):2508-2520. PubMed ID: 29721096
[No Abstract] [Full Text] [Related]
7. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody.
Wang CH; Huang YJ; Chang CW; Hsu WM; Peng CA
Nanotechnology; 2009 Aug; 20(31):315101. PubMed ID: 19597244
[TBL] [Abstract][Full Text] [Related]
8.
McNerney KO; Karageorgos S; Ferry GM; Wolpaw AJ; Burudpakdee C; Khurana P; Toland CN; Vemu R; Vu A; Hogarty MD; Bassiri H
Oncoimmunology; 2022; 11(1):2075204. PubMed ID: 35646475
[TBL] [Abstract][Full Text] [Related]
9. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
10. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
12. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
13. GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
Marx S; Wilken F; Wagner I; Marx M; Troschke-Meurer S; Zumpe M; Bien-Moeller S; Weidemeier M; Baldauf J; Fleck SK; Rauch BH; Schroeder HWS; Lode H; Siebert N
J Neurooncol; 2020 May; 147(3):577-585. PubMed ID: 32246395
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
Marston JC; Kennedy GD; Lapi SE; Hartman YE; Richardson MT; Modi HM; Warram JM
J Surg Res; 2019 Jul; 239():44-51. PubMed ID: 30798171
[TBL] [Abstract][Full Text] [Related]
15. Anti-Claudin-1 Conjugated to a Near-Infrared Fluorophore Targets Colon Cancer in PDOX Mouse Models.
Hollandsworth HM; Lwin TM; Amirfakhri S; Filemoni F; Batra SK; Hoffman RM; Dhawan P; Bouvet M
J Surg Res; 2019 Oct; 242():145-150. PubMed ID: 31077946
[TBL] [Abstract][Full Text] [Related]
16. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
17. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
18. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
[TBL] [Abstract][Full Text] [Related]
19. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
[TBL] [Abstract][Full Text] [Related]
20. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
